[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

ABSTRACT: This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC).

DISEASE(S): Malignancies Known To Overexpress Gastrin-releasing Peptide Receptors,Small Cell Lung Cancer,Colorectal Cancer,Small Cell Lung Carcinoma,Non Small Cell Lung Cancer,Prostate Cancer,Breast Cancer,Lung Neoplasms

PROVIDER: 2288221 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR